[go: up one dir, main page]

WO2002016360A3 - Nitrogenous heterocyclic compounds - Google Patents

Nitrogenous heterocyclic compounds Download PDF

Info

Publication number
WO2002016360A3
WO2002016360A3 PCT/US2001/041749 US0141749W WO0216360A3 WO 2002016360 A3 WO2002016360 A3 WO 2002016360A3 US 0141749 W US0141749 W US 0141749W WO 0216360 A3 WO0216360 A3 WO 0216360A3
Authority
WO
WIPO (PCT)
Prior art keywords
kinases
heterocyclic compounds
phosphorylation
pharmaceutically acceptable
inhibiting
Prior art date
Application number
PCT/US2001/041749
Other languages
French (fr)
Other versions
WO2002016360A2 (en
Inventor
Anjali Pandey
Robert M Scarborough
Kenji Matsuno
Michio Ichimura
Yuji Nomoto
Shigeki Fujiwara
Shinichi Ide
Eiji Tsukuda
Junko Irie
Shoji Oda
Original Assignee
Cor Therapeutics Inc
Kyowa Hakko Kogyo Kk
Anjali Pandey
Robert M Scarborough
Kenji Matsuno
Michio Ichimura
Yuji Nomoto
Shigeki Fujiwara
Shinichi Ide
Eiji Tsukuda
Junko Irie
Shoji Oda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cor Therapeutics Inc, Kyowa Hakko Kogyo Kk, Anjali Pandey, Robert M Scarborough, Kenji Matsuno, Michio Ichimura, Yuji Nomoto, Shigeki Fujiwara, Shinichi Ide, Eiji Tsukuda, Junko Irie, Shoji Oda filed Critical Cor Therapeutics Inc
Priority to US10/344,907 priority Critical patent/US20040259881A1/en
Priority to AU2001293207A priority patent/AU2001293207A1/en
Priority to EP01973652A priority patent/EP1309567A2/en
Publication of WO2002016360A2 publication Critical patent/WO2002016360A2/en
Publication of WO2002016360A3 publication Critical patent/WO2002016360A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.
PCT/US2001/041749 2000-08-18 2001-08-17 Nitrogenous heterocyclic compounds WO2002016360A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/344,907 US20040259881A1 (en) 2001-02-02 2001-08-17 Nitrogenous heterocyclic compounds
AU2001293207A AU2001293207A1 (en) 2000-08-18 2001-08-17 Nitrogenous heterocyclic compounds
EP01973652A EP1309567A2 (en) 2000-08-18 2001-08-17 Nitrogenous heterocyclic compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26612000P 2000-08-18 2000-08-18
US60/266,120 2000-08-18

Publications (2)

Publication Number Publication Date
WO2002016360A2 WO2002016360A2 (en) 2002-02-28
WO2002016360A3 true WO2002016360A3 (en) 2002-06-13

Family

ID=23013247

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/041749 WO2002016360A2 (en) 2000-08-18 2001-08-17 Nitrogenous heterocyclic compounds

Country Status (3)

Country Link
EP (1) EP1309567A2 (en)
AU (1) AU2001293207A1 (en)
WO (1) WO2002016360A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1309568B1 (en) 2000-08-18 2011-02-16 Millennium Pharmaceuticals, Inc. [(quinazolin-4-yl)piperazin-4-yl]thiocarboxamide compounds as inhibitors of the phosphorylation of a PDGF receptor
EP1315715B1 (en) 2000-08-18 2008-07-23 Millennium Pharmaceuticals, Inc. Quinazoline derivatives as kinase inhibitors
WO2002016362A2 (en) 2000-08-18 2002-02-28 Cor Therapeutics, Inc. Nitrogenous heterocyclic compounds
DE60144284D1 (en) 2000-11-01 2011-05-05 Millennium Pharm Inc NITROGENIC HETEROCYCLIC COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
WO2002072578A2 (en) 2001-03-08 2002-09-19 Millennium Pharmaceuticals (homo) piperazine substituted quinolines for inhibiting the phosphorylation of kinases
WO2005012264A1 (en) * 2003-07-30 2005-02-10 Ube Industries, Ltd. Process for producing 6,7-bis(2-methoxyethoxy)-quinazolin-4-one
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
CN101304743B (en) * 2005-09-19 2012-09-05 诺伊罗纳森特公司 Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration
AU2013211455B2 (en) * 2005-09-19 2017-12-07 Neuronascent, Inc. Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration
CN108358798A (en) * 2018-02-12 2018-08-03 黑龙江鑫创生物科技开发有限公司 A kind of method of micro passage reaction synthesis Tarceva intermediate
CN115108999B (en) * 2019-07-26 2023-11-03 暨南大学 A phenylpiperazine-quinazoline compound or its pharmaceutically acceptable salt, preparation method and use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0882717A1 (en) * 1996-10-01 1998-12-09 Kyowa Hakko Kogyo Kabushiki Kaisha Nitrogenous heterocyclic compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0882717A1 (en) * 1996-10-01 1998-12-09 Kyowa Hakko Kogyo Kabushiki Kaisha Nitrogenous heterocyclic compounds

Also Published As

Publication number Publication date
WO2002016360A2 (en) 2002-02-28
EP1309567A2 (en) 2003-05-14
AU2001293207A1 (en) 2002-03-04

Similar Documents

Publication Publication Date Title
EP1964839A3 (en) Quinazoline derivatives as kinase inhibitors
WO2002072578A3 (en) (homo) piperazine substituted quinolines for inhibiting the phosphorylation of kinases
WO2002016360A3 (en) Nitrogenous heterocyclic compounds
WO2002016362A3 (en) Nitrogenous heterocyclic compounds
WO2000043373A3 (en) Kinase inhibitors
WO2001019829A3 (en) Pyrazolopyrimidines as therapeutic agents
CA2400447A1 (en) Kinase inhibitors
WO2004054514A3 (en) C-6 modified indazolylpyrrolotriazines
WO2004001059A3 (en) Heterocyclic inhibitors of kinases
AU4470897A (en) Nitrogen-containing heterocyclic compounds
MY134848A (en) Pyrrolo[2,1-f] [1,2,4] triazine inhibitors of kinases
WO2005037836A3 (en) Imidazo ‘1, 5 - a ! pyrazine tyrosine kinase inhibitors
WO2003042172A3 (en) C-5 modified indazolylpyrrolotriazines
WO2000055159A3 (en) Substituted aza-oxindole derivatives
WO2004018419A3 (en) Benzimidazole quinolinones and uses thereof
CA2504933A1 (en) Methods and compositions for treating cancer using proteasome inhibitors
WO2002016361A3 (en) Nitrogenous heterocyclic compounds
WO2008079873A3 (en) Thiazolyl compounds useful as kinase inhibitors
WO2001012579A3 (en) New stilbenes with vascular damaging activity
WO2003092606A3 (en) Cholinesterase inhibitors to prevent injuries caused by chemicals
ATE502928T1 (en) NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
WO2003029428A3 (en) Use of calmodulin kinase ii inhibitors to treat myocardial dysfunction in structural heart disease
RU2007116863A (en) APPLICATION OF RENIN FOR PREVENTION OR TREATMENT OF DIASTOLIC DYSFUNCTION OR DIASTOLIC HEART FAILURE
WO2002094768A3 (en) Aza hydroxylated ethyl amine compounds
NO20055518L (en) 5-hydroxyindoles with N-oxide groups, use thereof as phosphodiesterase 4 inhibitor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001973652

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001973652

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10344907

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001973652

Country of ref document: EP